8-K: electroCore Appoints Co-CEOs, Expands Board

electroCore, Inc. announced the appointment of Joshua Lev and Mike Fox as Co-Chief Executive Officers and directors, effective September 8, 2026, alongside an expansion of the Board and updates to executive compensation and severance policies.

Summary

• Joshua Lev, previously Interim President and CFO, and Michael Fox, COO, have been appointed as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026.
• The Board size has been increased from six to eight members to accommodate the new directors.
• Employment agreements for both executives have been amended, increasing their base salaries and target annual cash bonuses.
• Both executives were granted 55,000 restricted stock units (RSUs) vesting over three years.
• The company also approved an Amended and Restated Executive Severance Policy and Third Amended and Restated Bylaws, the latter including updates for universal proxy rules and co-CEO structures.
• The company held its Annual Meeting on September 8, 2026, where directors were elected, an independent auditor was ratified, and executive compensation was approved by advisory vote.
• A press release on September 9, 2026, announced the Co-CEO appointments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating a strategic move to leverage complementary leadership strengths and a commitment to stability and growth.

Positives

• Appointment of two experienced leaders, Joshua Lev and Michael Fox, as Co-CEOs, leveraging their complementary strengths.
• Expansion of the Board of Directors to eight members, potentially bringing in diverse perspectives.
• Increased base salaries and target annual cash bonuses for the new Co-CEOs, reflecting their expanded roles and responsibilities.
• Grant of 55,000 RSUs to each Co-CEO, aligning their interests with long-term shareholder value.
• Updates to the Executive Severance Policy and Bylaws aim to modernize governance and clarify procedures, including compliance with universal proxy rules.
• Successful ratification of the independent auditor and approval of executive compensation by shareholders at the Annual Meeting.

Negatives

• The co-CEO structure, while intended to leverage complementary strengths, can sometimes lead to diffusion of responsibility or slower decision-making compared to a single CEO.
• Increased compensation for the Co-CEOs represents higher operating costs.
• The increase in Board size may lead to higher Board-related expenses.

Risks

• Potential for misaligned decision-making or slower execution due to the co-CEO structure.
• The effectiveness of the new leadership structure in driving future growth and achieving financial targets remains to be seen.
• The company's ability to achieve positive adjusted EBITDA and accelerate revenue growth under the new leadership is subject to market conditions and execution.

Future Outlook

The company aims to leverage the complementary strengths of its new Co-CEOs to enhance shareholder value, accelerate revenue growth, open new commercial channels, and achieve positive adjusted EBITDA. The focus remains on improving health and quality of life through innovative non-invasive bioelectronic technologies.

Management Comments

• "Following a deliberate leadership and succession process, it became clear that both Joshua and Mike possess the judgment, experience, vision, and leadership capabilities required of a Chief Executive Officer. The Company concluded that its strongest path forward was to bring their distinct and complementary strengths together in a shared leadership structure."
• "We were looking at two exceptional leaders, each with their unique qualities and capabilities to lead our Company. Most importantly, we concluded that both had demonstrated their ability to collaborate with each other in executing on the next phase of our strategy."
• "Their individual strengths are significant, but together, their combined experience, perspectives, and leadership capabilities create an opportunity to deliver more for our employees, customers, partners, and shareholders than either could achieve alone."
• "This is an exciting moment for electroCore. I have enormous respect for Mike as a leader and the improvements he has made to the commercial organization in such a short time. We bring different experiences and perspectives to the table, but we share a deep commitment to this Company, our people, and the opportunities ahead. I believe our partnership will allow us to lead with greater insight and accomplish even more together."
• "We have an opportunity to build on what makes electroCore strong while bringing together two complementary approaches to leadership and execution. Our shared goal is simple: to create greater value for the shareholders, move the Company forward, and help our people and organization reach their full potential. I am honored to take on this responsibility alongside Josh."
• "Strong organizations invest in identifying and developing leaders. Today, we are fortunate to have two leaders who have earned the confidence of the Board and the organization. We believe their partnership will strengthen our ability to innovate, execute, and create lasting value as we move into the future."

Industry Context

StockSavvy.ai notes that the appointment of Co-CEOs is an uncommon but strategic move, often employed by companies seeking to combine distinct leadership skill sets or ensure continuity during significant transitions. In the bioelectronic medicine and wellness sector, which is characterized by innovation and evolving regulatory landscapes, such a structure could allow electroCore to simultaneously focus on product development and commercial expansion.

Comparison to Industry Standards

• The appointment of Co-CEOs is not a widespread standard in the bioelectronic medicine or medical device industry, where single CEO leadership is more typical.
• Companies like Medtronic or Abbott typically operate with a single CEO, focusing on integrating diverse business units under one strategic vision.
• The compensation structure, including base salary and bonus targets, appears to be within the range for senior executives in mid-cap technology or healthcare companies, though specific industry benchmarks for Co-CEOs are less defined.
• The grant of RSUs vesting over three years is a common practice across the industry to incentivize long-term performance and retention.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The filing states that the Company is not aware of any transaction involving Mr. Lev or Mr. Fox which would require disclosure under Item 404(a) of Regulation S-K, other than their appointments as officers and directors.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through combined leadership, but also potential for uncertainty regarding the co-CEO structure's effectiveness. Increased compensation for executives may impact profitability.
• Employees: The co-CEO structure may provide clear leadership direction, but the impact on organizational culture and individual roles needs to be managed.
• Customers and Partners: Stability in leadership and continued focus on product development and commercialization should be positive.
• Creditors: The company's financial health and strategic direction remain key considerations, with the new leadership expected to focus on revenue growth and profitability.

Next Steps

• Continue to focus on building out a pipeline of potential indications.
• Accelerate revenue growth.
• Open new commercial channels.
• Achieve positive adjusted EBITDA.
• Build on the foundation of improving health and quality of life through innovative non-invasive bioelectronic technologies.

Key Dates

Recommendation

The appointment of Co-CEOs and related governance changes are significant internal developments. While presented positively, the long-term impact of a co-CEO structure on execution and value creation is uncertain. The company's focus on growth and profitability remains, but without new financial data or strategic shifts, a 'hold' recommendation is prudent pending further performance indicators.

Keywords

Co-CEO appointment, Board of Directors, Executive compensation, Severance policy, Bylaws amendment, Annual Meeting, Director election, Auditor ratification